News & Updates

Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.

A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.